Stocksigma LogoStocksigma Logo

Biocon Biologics Secures Positive EMA CHMP Opinion for Pertuzumab Biosimilar

Biocon Biologics, a wholly owned subsidiary of Biocon Limited, received a positive opinion from the EMA's CHMP on 21st Sep'26 recommending marketing

Biocon Biologics Secures Positive EMA CHMP Opinion for Pertuzumab Biosimilar

Biocon Ltd 路 Press Release 路 21 Sept 2026, 1:58 pm

Biocon Biologics Secures Positive EMA CHMP Opinion for Pertuzumab Biosimilar Biocon Biologics, a wholly owned subsidiary of Biocon Limited, received a positive opinion from the EMA's CHMP on 21st Sep'26 recommending marketing authorization for Pebrilzo (Pertuzumab biosimilar, 420 mg concentrate solution for infusion). The drug targets HER2-positive breast cancer across early, adjuvant, and metastatic stages. Notably, Pebrilzo is the first monoclonal antibody biosimilar recommended under the EMA's tailored clinical development approach based on analytical and pharmacokinetic data. Final European Commission marketing approval remains pending.

Original exchange filing (PDF)

More announcements from Biocon Ltd

All Biocon Ltd announcements